Improved safety and efficacy of (213)Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

BACKGROUND: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with (177)Lu-DOTATATE or (90)Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Ho Sze, Konijnenberg, Mark W., Daniels, Tamara, Nysus, Monique, Makvandi, Mehran, de Blois, Erik, Breeman, Wouter A., Atcher, Robert W., de Jong, Marion, Norenberg, Jeffrey P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118228/
https://www.ncbi.nlm.nih.gov/pubmed/27873240
http://dx.doi.org/10.1186/s13550-016-0240-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118228/
https://www.ncbi.nlm.nih.gov/pubmed/27873240
http://dx.doi.org/10.1186/s13550-016-0240-5

Ejemplares similares